Neutron Drugs & Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 19-12-2024
- Paid Up Capital ₹ 0.50 M
as on 19-12-2024
- Company Age 9 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 80.44%
(FY 2022)
- Profit 1.62%
(FY 2022)
- Ebitda 38.38%
(FY 2022)
- Net Worth 19.07%
(FY 2022)
- Total Assets 10.36%
(FY 2022)
About Neutron Drugs & Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Kamal Jain, Manisha Jain, Sonali Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233TG2015PTC101574
- Company No.
101574
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Nov 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Neutron Drugs & Pharmaceuticals Private Limited offer?
Neutron Drugs & Pharmaceuticals Private Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Organic Compounds, Calcium Carbonate Powder, Hand Sanitizers & Personal Hygiene, Hand Sanitizer & Disinfectant, Digestive System Drugs & Medicines, Antacid Drugs, Flavours & Aromatics, Food Acidulant, Animal Medicines & Health Care.
Who are the key members and board of directors at Neutron Drugs & Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Jain  | Director | 06-Nov-2015 | Current |
| Manisha Jain | Director | 06-Nov-2015 | Current |
| Sonali Jain | Director | 06-Nov-2015 | Current |
| Vinod Jain | Director | 06-Nov-2015 | Current |
Financial Performance and Corporate Structure Insights of Neutron Drugs & Pharmaceuticals.
Neutron Drugs & Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 80.44% increase. The company also saw a slight improvement in profitability, with a 1.62% increase in profit. The company's net worth Soared by an impressive increase of 19.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neutron Drugs & Pharmaceuticals?
In 2022, Neutron Drugs & Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kalpavraksh E-Business Solutions Private LimitedActive 8 years 6 monthsKamal Jain is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Neutron Drugs & Pharmaceuticals?
Unlock and access historical data on people associated with Neutron Drugs & Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neutron Drugs & Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neutron Drugs & Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
